GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » Current Accrued Expense

Aptabio Therapeutics (XKRX:293780) Current Accrued Expense : ₩0 Mil (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics Current Accrued Expense?

Aptabio Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2025 was ₩0 Mil.


Aptabio Therapeutics Current Accrued Expense Historical Data

The historical data trend for Aptabio Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics Current Accrued Expense Chart

Aptabio Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial - - - - -

Aptabio Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aptabio Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Aptabio Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Aptabio Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptabio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics Headlines

No Headlines